Curated News
By: NewsRamp Editorial Staff
March 26, 2026
NeuroOne's New System Ends 'Suicide Disease' Pain in 12 Patients
TLDR
- NeuroOne's OneRF Trigeminal Nerve Ablation System offers hospitals a competitive edge by enabling epilepsy and trigeminal neuralgia treatments with a single system, reducing capital investment.
- NeuroOne's multi-contact probe maps and ablates trigeminal nerves in a single cycle without repositioning, eliminating multiple sleep-wake cycles and shortening procedures to as little as 16 minutes.
- This technology alleviates the debilitating pain of trigeminal neuralgia, known as the suicide disease, improving patient comfort and quality of life for thousands suffering from chronic pain.
- NeuroOne's new ablation system treats trigeminal neuralgia with a multi-contact probe that can test and treat multiple nerve distributions without waking patients repeatedly during surgery.
Impact - Why it Matters
This development matters because trigeminal neuralgia affects approximately 150,000 people in the U.S., causing debilitating facial pain that disrupts daily life and has earned the grim nickname 'suicide disease' due to its severity. Current treatments often involve invasive surgeries with multiple anesthesia cycles, increasing patient discomfort and procedural time. NeuroOne's technology offers a more efficient, less traumatic alternative by enabling precise treatment in a single procedure, potentially reducing hospital stays, lowering healthcare costs, and significantly improving quality of life for sufferers. It represents a meaningful advance in neuromodulation, aligning with broader trends toward minimally invasive, patient-centric medical solutions.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has successfully completed the limited market release of its groundbreaking OneRF® Trigeminal Nerve Ablation System, following FDA 510(k) clearance in August 2025. The system, designed to treat the excruciating chronic pain condition known as trigeminal neuralgia—often called the "suicide disease"—demonstrated remarkable results across three leading medical centers. A total of 12 patients were treated, with all reporting freedom from pain following the procedure. Physicians highlighted the system's efficiency, with the fastest procedure completed in just 16 minutes, showcasing significant improvements over traditional methods.
A key innovation of NeuroOne's technology is its multi-contact probe, which addresses a major limitation of current ablative systems. Traditional procedures often require multiple sleep-wake cycles, where patients are repeatedly awakened to confirm pain localization and then re-anesthetized as the probe is repositioned. NeuroOne's probe enables precise mapping and ablation in a single cycle without repositioning, potentially revolutionizing patient comfort and procedural efficiency. Neurosurgeon Michael Staudt, MD, the Lincoln Endowed Chair in Brain Health at University Hospitals and an Associate Professor at Case Western Reserve University School of Medicine, emphasized that this new ablation probe represents a significant step forward, allowing testing and treatment of multiple nerve distributions without repositioning.
The OneRF® system uses the same NeuroOne Radiofrequency Generator already employed in epilepsy ablation procedures, allowing existing customers to add trigeminal neuralgia treatment without additional capital investment. This versatility, supporting multiple clinical applications with a single system, makes the NeuroOne platform highly attractive to hospitals evaluating new technology purchases. Dave Rosa, President and CEO of NeuroOne, noted that the results highlight clinical and procedural advantages, and the company is now expanding access to additional centers while exploring strategic partnership opportunities. For more information, visit nmtc1.com, and view the original release on www.newmediawire.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne's New System Ends 'Suicide Disease' Pain in 12 Patients
